Figure 7.

miR372 Promotes the erbB-2 through PKM2 in Liver Cancer Cells

(A) coIP with anti-PKM2 followed by western blotting with anti-histone H3 in the Hep3B cell lines infected with rLV and rLV-miR372, respectively. IgG IP as negative control is shown. INPUT refers to western blotting with anti-PKM2 and anti-histone H3. (B) coIP with anti-DHAC3 followed by western blotting with anti-histone H3 in the Hep3B cell lines infected with rLV and rLV-miR372, respectively, is shown. IgG IP as negative control is shown. INPUT refers to western blotting with anti-DHAC3 and anti-histone H3. (C) Western blotting analysis with anti-pH3T11 and anti-H3K9Ac in liver cancer cells Hep3B cell lines infected with rLV, rLV-miR372, and rLV-miR372 plus pGFP-V-RS-PKM2, respectively, is shown. β-actin as internal control is shown. (D) ChIP with anti-H3K9Ac followed by PCR with ErbB-2 promoter primers in the Hep3B cell lines infected with rLV and rLV-miR372, respectively, is shown. IgG CHIP as negative control is shown. PKM2 promoter as INPUT is shown. (E) The assay of ErbB-2 promoter luciferase activity is shown. Each value was presented as mean ± SEM. **p < 0.01. (F) Western blotting analysis with anti-ErbB-2 and RT-PCR with erbB-2 primers in liver cancer cells Hep3B cell lines infected with rLV, rLV-miR372, and rLV-miR372 plus pGFP-V-RS-PKM2, respectively, is shown. β-actin as internal control is shown.